Peer-Reviewed Journal Details
Mandatory Fields
Gardiner, GE;O'Flaherty, S;Casey, PG;Weber, A;McDonald, TL;Cronin, M;Hill, C;Ross, RP;Gahan, CGM;Shanahan, F
2009
April
Fems Immunology and Medical Microbiology
Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease
Validated
WOS: 13 ()
Optional Fields
ENTEROPATHOGENIC ESCHERICHIA-COLI PORCINE GASTROINTESTINAL-TRACT CITROBACTER-RODENTIUM COLONIC HYPERPLASIA BOVINE-MILK MUC3 MUCIN EXPRESSION PROBIOTICS GROWTH MICE
55
404
413
In vitro experiments confirmed that a 10-mer peptide derived from human mammary-associated serum amyloid A3 (M-SAA3) protected intestinal epithelial cells from enteropathogenic Escherichia coli (EPEC) adherence. The entire 42-mer human M-SAA3 protein was even more effective, reducing EPEC binding by 72% relative to untreated cells (P < 0.05), compared with 25% and 57% reductions for the human 10-mer and Lactobacillus GG, respectively. However, none of the M-SAA3 peptides reduced Salmonella invasion in vitro (P > 0.05). Each of the M-SAA3 10-mer peptides and the 42-mer was then administered orally to mice at 500 mu g day(-1) for 4 days before deliberate infection with either Citrobacter rodentium (mouse model of EPEC) or Salmonella Typhimurium. None of the peptides protected against Salmonella infection and the 42-mer may even increase infection, as there was a trend towards increased Salmonella counts in the liver and small intestine in 42-mer-treated mice compared with those in sodium acetate-treated control mice. Citrobacter counts were reduced in the caecum of mice administered the 42-mer relative to a scrambled 10-mer (P < 0.05), but not compared with the sodium acetate control and no reductions were observed in the faeces or colon. Overall, although promising anti-infective activity was demonstrated in vitro, neither the 42-mer M-SAA3 protein nor a 10-mer peptide derivative prevented enteric infection in the animal models tested.
MALDEN
0928-8244
10.1111/j.1574-695X.2009.00539.x
Grant Details